The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before
sharing sensitive information, make sure you’re on a federal
government site.
The
https://
ensures that you are connecting to the
official website and that any information you provide is encrypted
and transmitted securely.
As a library, NLM provides access to scientific literature. Inclusion in an NLM database does not imply endorsement of, or agreement with,
the contents by NLM or the National Institutes of Health.
Learn more about our disclaimer.
Zhongguo Fei Ai Za Zhi.
2023 Mar 20; 26(3): 204–216.
Language:
Chinese
|
English
肺腺癌中免疫微环境特征与
EGFR
突变状态的相关性研究
Correlation between Immune Microenvironment Features and
EGFR
Mutation Status in Lung Adenocarcinoma
,
,
,
,
,
,
,
,
,
,
,
,
,
,
and
Hongyu ZHU
210009 南京，南京医科大学附属肿瘤医院，江苏省肿瘤医院胸外科，江苏省肿瘤防治研究所，江苏省恶性肿瘤分子生物学及转化医学重点实验室
Peng CHEN
210009 南京，南京医科大学附属肿瘤医院，江苏省肿瘤医院胸外科，江苏省肿瘤防治研究所，江苏省恶性肿瘤分子生物学及转化医学重点实验室
Guozhang DONG
210009 南京，南京医科大学附属肿瘤医院，江苏省肿瘤医院胸外科，江苏省肿瘤防治研究所，江苏省恶性肿瘤分子生物学及转化医学重点实验室
Fanchen MENG
210009 南京，南京医科大学附属肿瘤医院，江苏省肿瘤医院胸外科，江苏省肿瘤防治研究所，江苏省恶性肿瘤分子生物学及转化医学重点实验室
Zhijun XIA
210009 南京，南京医科大学附属肿瘤医院，江苏省肿瘤医院胸外科，江苏省肿瘤防治研究所，江苏省恶性肿瘤分子生物学及转化医学重点实验室
Jing YOU
210009 南京，南京医科大学附属肿瘤医院，江苏省肿瘤医院胸外科，江苏省肿瘤防治研究所，江苏省恶性肿瘤分子生物学及转化医学重点实验室
Xiangru KONG
210009 南京，南京医科大学附属肿瘤医院，江苏省肿瘤医院胸外科，江苏省肿瘤防治研究所，江苏省恶性肿瘤分子生物学及转化医学重点实验室
Jintao WU
210009 南京，南京医科大学附属肿瘤医院，江苏省肿瘤医院胸外科，江苏省肿瘤防治研究所，江苏省恶性肿瘤分子生物学及转化医学重点实验室
Fangwei YUAN
210009 南京，南京医科大学附属肿瘤医院，江苏省肿瘤医院胸外科，江苏省肿瘤防治研究所，江苏省恶性肿瘤分子生物学及转化医学重点实验室
Xinyu YU
210009 南京，南京医科大学附属肿瘤医院，江苏省肿瘤医院胸外科，江苏省肿瘤防治研究所，江苏省恶性肿瘤分子生物学及转化医学重点实验室
Qinhong SUN
210009 南京，南京医科大学附属肿瘤医院，江苏省肿瘤医院胸外科，江苏省肿瘤防治研究所，江苏省恶性肿瘤分子生物学及转化医学重点实验室
Jinfu JI
210009 南京，南京医科大学附属肿瘤医院，江苏省肿瘤医院胸外科，江苏省肿瘤防治研究所，江苏省恶性肿瘤分子生物学及转化医学重点实验室
Siwei WANG
210009 南京，南京医科大学附属肿瘤医院，江苏省肿瘤医院胸外科，江苏省肿瘤防治研究所，江苏省恶性肿瘤分子生物学及转化医学重点实验室
Tongyan LIU
210009 南京，南京医科大学附属肿瘤医院，江苏省肿瘤医院胸外科，江苏省肿瘤防治研究所，江苏省恶性肿瘤分子生物学及转化医学重点实验室
Lin XU
210009 南京，南京医科大学附属肿瘤医院，江苏省肿瘤医院胸外科，江苏省肿瘤防治研究所，江苏省恶性肿瘤分子生物学及转化医学重点实验室
210009 南京，南京医科大学附属肿瘤医院，江苏省肿瘤医院胸外科，江苏省肿瘤防治研究所，江苏省恶性肿瘤分子生物学及转化医学重点实验室
Sung H,
Ferlay J,
Siegel RL,
et al.
Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
.
CA Cancer J Clin
,
2021,
71
(
3
): 209-249. doi: 10.3322/caac.21660
[
PubMed
] [
CrossRef
]
[
Google Scholar
]
2.
Zhang S,
Sun K,
Zheng R,
et al.
Cancer incidence and mortality in China, 2015
.
J Nat Cancer Center
,
2021,
1
(
1
): 2-11. doi: 10.1016/j.jncc.2020.12.001
[
CrossRef
]
[
Google Scholar
]
3.
Shigematsu H,
Lin L,
Takahashi T,
et al.
Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers
.
J Natl Cancer Inst
,
2005,
97
(
5
): 339-346. doi: 10.1093/jnci/dji055
[
PubMed
] [
CrossRef
]
[
Google Scholar
]
4.
Tan DS,
Mok TS,
Rebbeck TR.
Cancer genomics: Diversity and disparity across ethnicity and geography
.
J Clin Oncol
,
2016,
34
: 91-101. doi: 10.1200/JCO.2015.62.0096
[
PubMed
] [
CrossRef
]
[
Google Scholar
]
5.
Herbst RS,
Morgensztern D,
Boshoff C.
The biology and management of non-small cell lung cancer
.
Nature
,
2018,
553
(
7689
): 446-454. doi: 10.1038/nature25183
[
PubMed
] [
CrossRef
]
[
Google Scholar
]
6.
Garon EB,
Rizvi NA,
Hui R,
et al.
Pembrolizumab for the treatment of non-small-cell lung cancer
.
N Engl J Med
,
2015,
372
(
21
): 2018-2028. doi: 10.1056/NEJMoa1501824
[
PubMed
] [
CrossRef
]
[
Google Scholar
]
7.
West H,
McCleod M,
Hussein M,
et al.
Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial
.
Lancet Oncol
,
2019,
20
(
7
): 924-937. doi: 10.1016/S1470-2045(19)30167-6
[
PubMed
] [
CrossRef
]
[
Google Scholar
]
8.
Reck M,
Rodriguez-Abreu D,
Robinson AG,
et al.
Updated analysis of KEYNOTE-024: Pembrolizumab versus platinum-based chemotherapy for advanced non-small-cell lung cancer with PD-L1 tumor proportion score of 50% or greater
.
J Clin Oncol
,
2019,
37
(
7
): 537-546. doi: 10.1200/JCO.18.00149
[
PubMed
] [
CrossRef
]
[
Google Scholar
]
9.
Wiest N,
Majeed U,
Seegobin K,
et al.
Role of immune checkpoint inhibitor therapy in advanced EGFR-mutant non-small cell lung cancer
.
Front Oncol
,
2021,
11
: 751209. doi: 10.3389/fonc.2021.751209
[
PMC free article
]
[
PubMed
] [
CrossRef
]
[
Google Scholar
]
10.
Shi C,
Wang Y,
Xue J,
et al.
Immunotherapy for EGFR-mutant advanced non-small-cell lung cancer: Current status, possible mechanisms and application prospects
.
Front Immunol
,
2022,
13
: 940288. doi: 10.3389/fimmu.2022.940288
[
PMC free article
]
[
PubMed
] [
CrossRef
]
[
Google Scholar
]
11.
Friedlaender A,
Tsantoulis P,
Chevallier M,
et al.
The impact of variant allele frequency in EGFR mutated NSCLC patients on targeted therapy
.
Front Oncol
,
2021,
11
: 644472. doi: 10.3389/fonc.2021.644472
[
PMC free article
]
[
PubMed
] [
CrossRef
]
[
Google Scholar
]
12.
Hastings K,
Yu HA,
Wei W,
et al.
EGFR mutation subtypes and response to immune checkpoint blockade treatment in non-small-cell lung cancer
.
Ann Oncol
,
2019,
30
(
8
): 1311-1320. doi: 10.1093/annonc/mdz141
[
PMC free article
]
[
PubMed
] [
CrossRef
]
[
Google Scholar
]
13.
Brindel A,
Althakfi W,
Barritault M,
et al.
Uncommon mutations in lung adenocarcinoma: features and response to tyrosine kinase inhibitors
.
J Thorac Dis
,
2020,
12
(
9
): 4643-4650. doi: 10.21037/jtd-19-3790
[
PMC free article
]
[
PubMed
] [
CrossRef
]
[
Google Scholar
]
14.
Chen K,
Cheng G,
Zhang F,
et al.
PD-L1 expression and T cells infiltration in patients with uncommon EGFR-mutant non-small cell lung cancer and the response to immunotherapy
.
Lung Cancer
,
2020,
142
: 98-105. doi: 10.1016/j.lungcan.2020.02.010
[
PubMed
] [
CrossRef
]
[
Google Scholar
]
15.
Tan WCC,
Nerurkar SN,
Cai HY,
et al.
Overview of multiplex immunohistochemistry/immunofluorescence techniques in the era of cancer immunotherapy
.
Cancer Commun (Lond)
,
2020,
40
(
4
): 135-153. doi: 10.1002/cac2.12023
[
PMC free article
]
[
PubMed
] [
CrossRef
]
[
Google Scholar
]
16.
Vansteenkiste J,
Wauters E,
Reymen B,
et al.
Current status of immune checkpoint inhibition in early-stage NSCLC
.
Ann Oncol
,
2019,
30
(
8
): 1244-1253. doi: 10.1093/annonc/mdz175
[
PubMed
] [
CrossRef
]
[
Google Scholar
]
17.
Toki MI,
Mani N,
Smithy JW,
et al.
Immune marker profiling and programmed death ligand 1 expression across NSCLC mutations
.
J Thorac Oncol
,
2018,
13
(
12
): 1884-1896. doi: 10.1016/j.jtho.2018.09.012
[
PMC free article
]
[
PubMed
] [
CrossRef
]
[
Google Scholar
]
18.
Yang L,
He YT,
Dong S,
et al.
Single-cell transcriptome analysis revealed a suppressive tumor immune microenvironment in EGFR mutant lung adenocarcinoma
.
J Immunother Cancer
,
2022,
10
(
2
): e003534. doi: 10.1136/jitc-2021-003534
[
PMC free article
]
[
PubMed
] [
CrossRef
]
[
Google Scholar
]
19.
Zhu GS,
Li YW,
Shi RF,
et al.
Immune microenvironment comparation study between EGFR mutant and EGFR wild type lung adenocarcinoma patients based on TCGA database
.
Zhongguo Fei Ai Za Zhi
,
2021,
24
(
4
): 236-244.
[
PMC free article
]
[
PubMed
]
[
Google Scholar
]
[朱光胜,
et al.
基于TCGA数据库的EGFR突变型与野生型肺腺癌患者免疫微环境的差异性分析
.
中国肺癌杂志
,
2021,
24
(
4
): 236-244.] doi: 10.3779/j.issn.1009-3419.2021.102.15
[
CrossRef
]
[
Google Scholar
]
20.
Gieszer B,
Megyesfalvi Z,
Dulai V,
et al.
EGFR variant allele frequency predicts EGFR-TKI efficacy in lung adenocarcinoma: a multicenter study
.
Transl Lung Cancer Res
,
2021,
10
(
2
): 662-674. doi: 10.21037/tlcr-20-814
[
PMC free article
]
[
PubMed
] [
CrossRef
]
[
Google Scholar
]
Articles from
Chinese Journal of Lung Cancer
are provided here courtesy of
Editorial office of Chinese Journal of Lung Cancer
